安捷伦获FDA批准用于卵巢癌伴随诊断 - Femtech Insider
Agilent Receives FDA Approval for Companion Diagnostic in Ovarian Cancer - Femtech Insider
生命科学资讯
生物技术与制药领域的最新动态
沃特斯是否比赛默飞世尔科技更值得买入？- Trefis
Is Waters a Better Buy Than Thermo Fisher Scientific? - Trefis
10x Genomics Inc (TXG) 2025年第四季度财报电话会议亮点：业绩超越预期 - GuruFocus
10x Genomics Inc (TXG) Q4 2025 Earnings Call Highlights: Surpass - GuruFocus
10x Genomics第四季度财报电话会议要点 - MarketBeat
10x Genomics Q4 Earnings Call Highlights - MarketBeat
10x Genomics第四季度财报电话会议要点 - MarketBeat
10x Genomics Q4 Earnings Call Highlights - MarketBeat
Ultragenyx在经历艰难的2025年后将裁员约130人
Ultragenyx to lay off about 130 employees after rough 2025
与预期相比：10x Genomics (TXG) 第四季度财报关键指标解析 - 雅虎财经
Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
与预期相比，10x Genomics（TXG）第四季度财报：关键指标一览 - 纳斯达克
Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics - Nasdaq
Thermo Fisher Scientific Inc. (TMO)：我们对其内在价值的计算——收购者倍数法
Thermo Fisher Scientific Inc. (TMO): Our Calculation of Intrinsic Value - The Acquirer's Multiple
财报汇总：Neurocrine股价下滑，Alnylam力抗质疑，Ascendis瞄准竞争对手
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor
赛默飞世尔发行38亿美元票据用于收购 - TipRanks
Thermo Fisher Issues $3.8 Billion Notes for Acquisition - TipRanks
10x Genomics (NASDAQ:TXG) 2025财年第四季度业绩亮眼 - 雅虎财经
10x Genomics (NASDAQ:TXG) Delivers Impressive Q4 CY2025 - Yahoo Finance
10x Genomics (NASDAQ:TXG) 发布季度财报，每股收益超出预期0.07美元 - MarketBeat
10x Genomics (NASDAQ:TXG) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
10x Genomics：第四季度收益快照 - WKYC
10x Genomics: Q4 Earnings Snapshot - WKYC
10x Genomics（纳斯达克：TXG）缩小2025年亏损，预期2026年实现温和增长 - Stock Titan
10x Genomics (NASDAQ: TXG) narrows 2025 losses and guides to modest 2026 growth - Stock Titan
10x Genomics公布2025年第四季度及全年财务业绩，并提供2026年展望 - 美通社
10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026 - PR Newswire
Icon公司披露内部会计调查后股价暴跌40%
Icon's stock drops 40% after disclosing internal accounting probe
Icon公司股价暴跌，首席风险官披露会计调查并撤回2025年业绩指引。
Icon shares plummet after CRO reveals accounting investigation, pulls 2025 guidance
灵北公司偏头痛预防治疗在早期试验受挫后二期临床试验成功。
Lundbeck’s migraine prevention treatment sees ph. 2 success after trial’s earlier setback
艾伯维就肉毒杆菌素入选IRA谈判提起法律诉讼。
AbbVie sues over selection of Botox for IRA negotiations